IN2014CN02591A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02591A
IN2014CN02591A IN2591CHN2014A IN2014CN02591A IN 2014CN02591 A IN2014CN02591 A IN 2014CN02591A IN 2591CHN2014 A IN2591CHN2014 A IN 2591CHN2014A IN 2014CN02591 A IN2014CN02591 A IN 2014CN02591A
Authority
IN
India
Prior art keywords
etanercept
combination
present
fragmentation
arginine
Prior art date
Application number
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of IN2014CN02591A publication Critical patent/IN2014CN02591A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention is a stable aqueous pharmaceutical composition comprising etanercept in combination with stabilizers to reduce instability aggregation misfolding and/or fragmentation of the etanercept during storage of the formulation; said stabilizer comprising a combination of a sugar and a polyol. Various technical terms used in the following discussion are defined below in the section entitled 'Definitions' and throughout the remainder of the specification. The stabilized etanercept formulations of the present invention which ar optionally and preferably free of arginine elicit long term storage stability.
IN2591CHN2014 2011-10-18 2012-10-18 IN2014CN02591A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060748 WO2013059412A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Publications (1)

Publication Number Publication Date
IN2014CN02591A true IN2014CN02591A (en) 2015-06-26

Family

ID=48136153

Family Applications (3)

Application Number Title Priority Date Filing Date
IN2592CHN2014 IN2014CN02592A (en) 2011-10-18 2012-10-18
IN2591CHN2014 IN2014CN02591A (en) 2011-10-18 2012-10-18
IN2527CHN2014 IN2014CN02527A (en) 2011-10-18 2012-10-18

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2592CHN2014 IN2014CN02592A (en) 2011-10-18 2012-10-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2527CHN2014 IN2014CN02527A (en) 2011-10-18 2012-10-18

Country Status (27)

Country Link
US (21) US9302002B2 (en)
EP (6) EP2768854A4 (en)
JP (6) JP6220789B2 (en)
KR (7) KR20140091705A (en)
CN (6) CN104010654B (en)
AR (6) AR088383A1 (en)
AU (6) AU2012326170B2 (en)
BR (6) BR112014009022A2 (en)
CA (6) CA2851639C (en)
CY (1) CY1121843T1 (en)
DK (1) DK2768525T3 (en)
EA (6) EA027325B1 (en)
ES (1) ES2734070T3 (en)
HK (6) HK1200719A1 (en)
HR (1) HRP20191215T1 (en)
HU (1) HUE045624T2 (en)
IL (6) IL231827A0 (en)
IN (3) IN2014CN02592A (en)
LT (1) LT2768525T (en)
MX (7) MX367054B (en)
PL (1) PL2768525T3 (en)
PT (1) PT2768525T (en)
RS (1) RS59179B1 (en)
SG (6) SG11201401576WA (en)
SI (1) SI2768525T1 (en)
TW (6) TWI595883B (en)
WO (6) WO2013059410A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (en) 2005-06-14 2020-07-31 Amgen Inc Self-buffering protein formulations
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
JP6220789B2 (en) * 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド Etanercept formulation stabilized by a combination of sugar and polyol
BR112015000203A2 (en) * 2012-07-09 2017-06-27 Coherus Biosciences Inc etanercept formulations exhibiting marked reduction in sub-visible particles
CN104902914B (en) * 2012-09-11 2019-01-01 科荣生生物科学公司 The Etanercept of high-purity and excellent yield correctly folded
RU2663727C2 (en) * 2013-05-02 2018-08-08 Мабксьенсе С.А. Alternative compositions for tnfr:fc chimerical polypeptides
WO2015056613A1 (en) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Stabilized polypeptide aqueous preparation
MX2016004605A (en) * 2013-10-24 2016-11-14 Astrazeneca Ab Stable, aqueous antibody formulations.
US9700595B2 (en) 2013-11-29 2017-07-11 Ares Trading Sa Liquid formulation of a fusion protein comprising TNFR and Fc region
IS3008B (en) 2014-05-14 2018-12-15 Calor ehf A peptide or protein stabilizing formulation
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
CA2970577A1 (en) * 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
EP3236942A1 (en) * 2014-12-23 2017-11-01 Drug Discovery Laboratory AS Protein compositions and use thereof
IL253218B (en) 2014-12-31 2022-08-01 Lg Chemical Ltd Method for preparing tnfr-fc fusion protein containing target content of impurities
CN104694355B (en) * 2015-03-20 2016-09-28 吉林大学 Radix Puerariae liver-protection health-care wine and preparation method thereof
MX2015010517A (en) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Etanercept composition having improved stability.
JP5938762B1 (en) * 2015-09-01 2016-06-22 日揮株式会社 Microcapsule preparation and production method thereof
CN105748414A (en) * 2016-03-02 2016-07-13 张光泉 Anti-infection micafungin freeze-drying composition and preparation method thereof
JPWO2017179683A1 (en) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Stabilized pharmaceutical composition of Micafungin
MX2019004580A (en) * 2016-10-21 2019-08-12 Amgen Inc Pharmaceutical formulations and methods of making the same.
WO2018080196A2 (en) 2016-10-28 2018-05-03 (주)셀트리온 Stable pharmaceutical formulation
MX2017013995A (en) * 2017-10-31 2019-05-01 Probiomed S A De C V Stable pharmaceutical formulation of a fusion protein.
CN111110842B (en) * 2017-11-30 2020-12-11 百奥泰生物制药股份有限公司 Liquid preparation of humanized antibody for treating IL-6 related diseases
KR102494021B1 (en) * 2017-12-22 2023-02-06 삼성바이오에피스 주식회사 Liquid composition containing VEGF antagonist
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (en) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
KR20220122993A (en) * 2019-11-26 2022-09-05 코메라 라이프 사이언시스, 인코포레이티드 Excipient compounds for biopolymer formulations
IL305010A (en) 2021-02-17 2023-10-01 Arecor Ltd Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (en) * 2022-01-25 2023-04-14 江苏广承药业有限公司 Loratadine liquid preparation

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (en) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
BR0108193A (en) 2000-02-10 2003-02-25 Wyeth Corp Process for treating or inhibiting cell damage or cell death
ES2644275T3 (en) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibodies
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
JP4583762B2 (en) * 2002-02-27 2010-11-17 イミュネックス・コーポレーション Polypeptide preparation
BRPI0407649A (en) 2003-02-28 2006-02-21 Ares Trading Sa liquid formulation of tumor necrosis factor binding proteins, process for preparing liquid formulation of tumor necrosis factor binding proteins and formulation presentation form
WO2004082715A1 (en) 2003-03-20 2004-09-30 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
CN100509847C (en) 2003-08-01 2009-07-08 安美基公司 Crystalline tumor necrosis factor receptor 2 polypeptides
RS20060259A (en) 2003-10-14 2008-08-07 Intermune Inc., Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005082377A1 (en) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. INHIBITOR FOR LOWERING IN THE ACTIVITY OF ANTIHUMAN TNF-α ANTIBODY
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
JP5068167B2 (en) 2005-06-10 2012-11-07 中外製薬株式会社 Stabilizer for protein preparation containing meglumine and use thereof
ES2776657T3 (en) * 2005-06-14 2020-07-31 Amgen Inc Self-buffering protein formulations
AR058567A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co FORMULATIONS OF STABLE PROTEINS
JP5405122B2 (en) 2005-12-21 2014-02-05 ワイス・エルエルシー Low viscosity protein formulations and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080038753A1 (en) * 2006-08-01 2008-02-14 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
MX2009004519A (en) 2006-11-03 2009-05-12 Wyeth Corp Glycolysis-inhibiting substances in cell culture.
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
KR20090127326A (en) 2007-03-02 2009-12-10 와이어쓰 Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
CN103977404A (en) * 2007-06-14 2014-08-13 比奥根艾迪克Ma公司 Antibody formulations
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
MX2010007728A (en) * 2008-01-15 2010-12-21 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same.
EP2260054B1 (en) 2008-02-29 2015-06-03 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
HUE048980T2 (en) 2009-08-11 2020-08-28 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2011134920A1 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell culture medium
CN102946858B (en) * 2010-05-10 2015-09-30 英塔斯制药有限公司 The liquid preparation of the polypeptide containing immunoglobulin Fc
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2013536683A (en) 2010-08-31 2013-09-26 フリエスランド ブランズ ビー．ブイ． Culture medium for eukaryotic cells
KR20130142128A (en) 2010-10-11 2013-12-27 애브비 인코포레이티드 Processes for purification of proteins
JP5996631B2 (en) * 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト Stable pharmaceutical solution of TNFR: Fc fusion protein
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
WO2013003731A2 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
KR102061355B1 (en) * 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 Arginine-free tnfr : fc- fusion polypeptide compositions and methods of use
KR102108663B1 (en) 2011-07-01 2020-05-07 암젠 인크 Mammalian cell culture
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
JP6223338B2 (en) 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム Method for producing active TNFR-Fc fusion protein
JP6220789B2 (en) * 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド Etanercept formulation stabilized by a combination of sugar and polyol
CN104902914B (en) 2012-09-11 2019-01-01 科荣生生物科学公司 The Etanercept of high-purity and excellent yield correctly folded

Also Published As

Publication number Publication date
EP2768533A1 (en) 2014-08-27
IL231824A0 (en) 2014-05-28
EP2768525A4 (en) 2015-07-15
JP6199298B2 (en) 2017-09-20
HK1200722A1 (en) 2015-08-14
BR112014009031A2 (en) 2017-05-09
US20180193463A1 (en) 2018-07-12
CN104010654A (en) 2014-08-27
CA2851646A1 (en) 2013-04-25
TW201325606A (en) 2013-07-01
US10980885B2 (en) 2021-04-20
HRP20191215T1 (en) 2019-10-04
KR20140083037A (en) 2014-07-03
HK1200720A1 (en) 2015-08-14
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
HK1200851A1 (en) 2015-08-14
CA2851642A1 (en) 2013-04-25
AU2012326080A1 (en) 2014-04-24
AR088380A1 (en) 2014-05-28
IL231828A0 (en) 2014-05-28
JP6113176B2 (en) 2017-04-12
US10888619B2 (en) 2021-01-12
EA027325B1 (en) 2017-07-31
US20130108633A1 (en) 2013-05-02
US20200405865A1 (en) 2020-12-31
JP2014530254A (en) 2014-11-17
WO2013059405A1 (en) 2013-04-25
CN104011073B (en) 2017-08-25
MX2014004733A (en) 2015-05-15
TW201325609A (en) 2013-07-01
MX2014004725A (en) 2015-02-05
EA026410B1 (en) 2017-04-28
EA201490802A1 (en) 2014-08-29
AU2012326170A1 (en) 2014-04-24
BR112014009131A2 (en) 2017-06-13
MX2014004734A (en) 2015-05-15
IL231825A0 (en) 2014-05-28
CN104010657A (en) 2014-08-27
EP2768531A4 (en) 2015-03-11
AR088379A1 (en) 2014-05-28
CN104011073A (en) 2014-08-27
CN103998060B (en) 2016-12-21
US20130101640A1 (en) 2013-04-25
KR20140097184A (en) 2014-08-06
TW201325611A (en) 2013-07-01
BR112014009073A2 (en) 2017-05-09
EA201490804A1 (en) 2014-09-30
CY1121843T1 (en) 2020-07-31
EA201490815A1 (en) 2014-09-30
US20190290767A1 (en) 2019-09-26
KR20140091705A (en) 2014-07-22
JP6220788B2 (en) 2017-10-25
KR20140091707A (en) 2014-07-22
US20190290766A1 (en) 2019-09-26
BR112014009022A2 (en) 2017-05-02
AR088381A1 (en) 2014-05-28
SG11201401562RA (en) 2014-09-26
SI2768525T1 (en) 2019-10-30
AU2012326171B2 (en) 2017-03-09
RS59179B1 (en) 2019-10-31
AU2012326080B2 (en) 2017-02-16
IL231827A0 (en) 2014-05-28
US20190290765A1 (en) 2019-09-26
CN103998061A (en) 2014-08-20
HK1200721A1 (en) 2015-08-14
US20130108632A1 (en) 2013-05-02
BR112014009146A2 (en) 2017-06-13
HK1200719A1 (en) 2015-08-14
US20190314499A1 (en) 2019-10-17
EA025267B1 (en) 2016-12-30
US20190314500A1 (en) 2019-10-17
WO2013059406A1 (en) 2013-04-25
CA2851639C (en) 2020-12-29
ES2734070T3 (en) 2019-12-04
EP2768532A1 (en) 2014-08-27
US10987405B2 (en) 2021-04-27
PT2768525T (en) 2019-07-17
US20130101584A1 (en) 2013-04-25
TW201325610A (en) 2013-07-01
EA028520B1 (en) 2017-11-30
AR088382A1 (en) 2014-05-28
JP2014530255A (en) 2014-11-17
KR20140091706A (en) 2014-07-22
KR20200008021A (en) 2020-01-22
AU2012326170B2 (en) 2016-12-22
US20190298837A1 (en) 2019-10-03
SG11201401567YA (en) 2014-07-30
MX367054B (en) 2019-08-02
BR112014009146A8 (en) 2017-06-20
JP6110393B2 (en) 2017-04-05
WO2013059407A1 (en) 2013-04-25
SG11201401563SA (en) 2014-09-26
US20160199489A1 (en) 2016-07-14
EP2768533A4 (en) 2015-03-11
EP2768854A4 (en) 2015-03-11
PL2768525T3 (en) 2019-10-31
AU2012326168A1 (en) 2014-04-24
EA201490817A1 (en) 2014-09-30
TW201325607A (en) 2013-07-01
US20190328875A1 (en) 2019-10-31
JP2014530862A (en) 2014-11-20
TW201325608A (en) 2013-07-01
SG11201401519RA (en) 2014-07-30
CA2851651A1 (en) 2013-04-25
US9801942B2 (en) 2017-10-31
US20160317667A1 (en) 2016-11-03
US10980884B2 (en) 2021-04-20
SG11201401576WA (en) 2014-10-30
AU2012326082A1 (en) 2014-04-24
EP2768535A1 (en) 2014-08-27
US11129876B2 (en) 2021-09-28
US10213508B2 (en) 2019-02-26
EA201490801A1 (en) 2014-09-30
MX2014004726A (en) 2015-05-15
WO2013059408A1 (en) 2013-04-25
EA201490803A1 (en) 2014-09-30
CN103998060A (en) 2014-08-20
CA2851639A1 (en) 2013-04-25
BR112014009087A2 (en) 2017-04-18
AR088460A1 (en) 2014-06-11
JP2014530863A (en) 2014-11-20
IN2014CN02592A (en) 2015-09-04
CA2851635A1 (en) 2013-04-25
AU2012326082B2 (en) 2016-12-15
US20190216930A1 (en) 2019-07-18
TWI644681B (en) 2018-12-21
JP2014530256A (en) 2014-11-17
LT2768525T (en) 2019-09-25
EP2768531A1 (en) 2014-08-27
IL231829A0 (en) 2014-05-28
WO2013059412A1 (en) 2013-04-25
CA2851628A1 (en) 2013-04-25
HUE045624T2 (en) 2020-01-28
MX2014004732A (en) 2015-05-15
EA025663B1 (en) 2017-01-30
US9302002B2 (en) 2016-04-05
JP2014530864A (en) 2014-11-20
US20190290768A1 (en) 2019-09-26
US10772963B2 (en) 2020-09-15
IL231826A0 (en) 2014-05-28
IN2014CN02527A (en) 2015-06-26
SG11201401517VA (en) 2014-09-26
TWI595883B (en) 2017-08-21
KR102163150B1 (en) 2020-10-08
US11135267B2 (en) 2021-10-05
EP2768532A4 (en) 2015-03-11
DK2768525T3 (en) 2019-07-22
AU2012326168B2 (en) 2016-12-15
EP2768535A4 (en) 2015-03-11
US20180125982A1 (en) 2018-05-10
WO2013059410A1 (en) 2013-04-25
US20190184017A1 (en) 2019-06-20
CN104010654B (en) 2017-10-27
CN104010658A (en) 2014-08-27
MX2019009176A (en) 2019-10-07
JP6220789B2 (en) 2017-10-25
AU2012326171A1 (en) 2014-04-24
EP2768525A1 (en) 2014-08-27
EP2768854A1 (en) 2014-08-27
AU2012326084B2 (en) 2016-12-15
AR088383A1 (en) 2014-05-28
EP2768525B1 (en) 2019-06-19
AU2012326084A1 (en) 2014-04-17
US20180028668A1 (en) 2018-02-01
KR102068462B1 (en) 2020-01-22
HK1200718A1 (en) 2015-08-14
US20190314498A1 (en) 2019-10-17
US9943601B2 (en) 2018-04-17
MX2014004728A (en) 2015-05-15
US9770510B2 (en) 2017-09-26
KR20140079491A (en) 2014-06-26
JP6104922B2 (en) 2017-03-29
BR112014009131A8 (en) 2017-06-20
US10376588B2 (en) 2019-08-13
TWI619504B (en) 2018-04-01

Similar Documents

Publication Publication Date Title
IN2014CN02591A (en)
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
BR112015008186A2 (en) formulation of a stable, low viscosity antibody
PH12014502778A1 (en) Antibody formulation
MX2016009666A (en) Topical delivery of skin compositions having low ph.
GEP201706734B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
MY188598A (en) Dexmedetomidine premix formulation
MX340463B (en) Liquid formulations for long-acting g-csf conjugate.
WO2012076670A3 (en) Antibody formulation
AR084932A1 (en) OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
GEP20146177B (en) Pyrazole compounds as crth2 antagonists
MX2016014411A (en) Liquid formulation comprising gm-csf neutralizing compound.
MX2016012870A (en) Stable factor viii formulations with low sugar-glycine.
MX359106B (en) INJECTABLE PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN and TRAMADOL.
IN2014CN04119A (en)
WO2012157921A3 (en) Composition for transdermal administration, containing rivastigmine or salt thereof
PL404379A1 (en) Ointment
TH142232A (en) Stable sunscreen composition
EA201591218A1 (en) METHODS AND COMPOSITIONS FOR THE INTRODUCTION OF OXYBUTININ